ArticleFrontiers in oncology2025
Clinical features and prognostic analysis of 120 patients with oropharyngeal squamous cell carcinoma: a hospital-based real-world study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oropharyngeal cancer mortality in the United States, 1999-2023: a surveillance analysis using CDC WONDER.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical characteristics and current treatment status of oropharyngeal squamous cell carcinoma (OPSCC) patients in Shanxi Province, China, and to examine the relationship between these factors and human papillomavirus (HPV) status, as well as identify risk factors influencing prognosis. Methods: We retrospectively analyzed the medical records of 120 OPSCC patients from two tertiary hospitals in Shanxi Province. Statistical analyses were performed to assess the relationship between various clinicopathological factors, treatment modalities, and p16 status, as well as their impact on patient prognosis. Results: The most common sub-anatomical sites of OPSCC were the tonsils and the base of the tongue, with a significantly higher proportion of p16-positive cases compared to other sub-sites (P = 0.033). The majority of cases were poorly differentiated squamous cell carcinoma (63 cases, 52.5%), of which 71.4% were p16-positive (P = 0.002). Patients with p16-positive OPSCC were more likely to present with a neck mass as the initial symptom (73.2%, P = 0.019). Overall, p16-positive OPSCC patients had a better prognosis (P = 0.008); however, p16-positive patients with primary tumors located in the soft palate and posterior pharyngeal wall did not show a significant prognostic advantage compared to p16-negative patients. Surgical treatment did not improve survival rates for OPSCC patients, particularly in the p16-positive group, where the survival curves showed significant separation approximately one year after treatment, indicating better outcomes in the non-surgical group. Conclusion: In North China's Shanxi Province, the incidence of HPV-associated OPSCC has surpassed that of OPSCC caused by smoking and alcohol use. p16-positive patients with primary tumors located in the soft palate and posterior pharyngeal wall have a poor prognosis, indicating that treatment de-escalation should be approached with caution. Traditional open surgical treatment, without consideration of HPV status, does not appear to benefit patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.